Evidence map›Paper›PMID 28807937›Full record

ArticleCancer research2017

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Mianen Sun, Pan Tong, Wen Kong, Baijun Dong, Yiran Huang, In Young Park, Lijun Zhou, Xian-De Liu, Zhiyong Ding, Xuesong Zhang and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Cross-Cancer Pleiotropic Associations with Lung Cancer Risk in African Americans.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Mianen SunDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Pan TongDepartment of Bioinformatics and Computational Biology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Wen KongDepartment of Urology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Baijun DongDepartment of Urology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yiran HuangDepartment of Urology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
In Young ParkInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Lijun ZhouDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Xian-De LiuDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Zhiyong DingDepartment of System Biology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Xuesong ZhangDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Shanshan BaiDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Peter GermanDepartment of Genitourinary Medical Oncology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Reid PowellInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Quan WangInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Xuefei TongInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Nizar M TannirInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Surena F MatinDepartment of Urology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
W Kimryn RathmellDepartment of Urology, University of North Carolina, Chapel Hill, North Carolina.
Gregory N FullerDepartment of Pathology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Ian E McCutcheonDepartment of Neurosurgery, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Cheryl L WalkerInstitute of Biosciences and Technology, Texas A&M University Health Science Center, Bryan, Texas.
Jing WangDepartment of Bioinformatics and Computational Biology, University of Texas at MD Anderson Cancer Center, Houston, Texas.
Eric Jonasch
The University of Texas MD Anderson Cancer Center · USTexas A&M Health Science Center · USShanghai Jiao Tong University · CNUniversity of North Carolina at Chapel Hill · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Chromophobe renal cell carcinoma (ChRCC) is characterized by major changes in chromosomal copy number (CN). No model is available to precisely elucidate the molecular drivers of this tumor type. HNF1B is a master regulator of gene expression. Here, we report that the transcription factor HNF1B is downregulated in the majority of ChRCC and that the magnitude of

Indexed as

AneuploidyAnimalsApoptosisCarcinoma, Renal CellCell CycleCell Cycle ProteinsCell ProliferationCells, CulturedChromosomal InstabilityEmbryo, MammalianFibroblastsHepatocyte Nuclear Factor 1-betaHumansKidney NeoplasmsMad2 ProteinsMiceBUB1B protein, humanCell Cycle ProteinsHepatocyte Nuclear Factor 1-betaHNF1B protein, humanMAD2L1 protein, humanMad2 ProteinsProtein Serine-Threonine Kinases

Identifiers

PMID28807937
PMCPMC5626626
OpenAlexW2748019023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.